Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has approved a plan to spin off its biopharmaceutical subsidiary Fosun Adgenvax for a separate listing on the Main Board of the Hong Kong Stock Exchange, in a move designed to tap international capital markets and sharpen the group’s portfolio focus. Fosun Adgenvax intends to issue H shares with a par value of RMB1.00, with the initial offering capped at no more than 25% of its enlarged share capital, plus an over-allotment option of up to 15% of the initial size, via a combined Hong Kong public offer and international placing to global institutional and other qualified investors. The final pricing and size will be set based on market conditions, investor demand, and sector valuations, signaling Fosun Pharma’s effort to unlock value in its biopharma assets and potentially strengthen its competitive position and funding capacity for future growth.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare conglomerate engaged in pharmaceutical manufacturing, research and development, and related healthcare services through a portfolio of subsidiaries. The group focuses on innovative and biopharmaceutical products, leveraging listings in Hong Kong to access global capital and institutional investors for its healthcare ventures.
Average Trading Volume: 4,345,465
Technical Sentiment Signal: Hold
Current Market Cap: HK$76.32B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.